We invite you to engage in an interactive roundtable led by EverythingALS consortia members of neurologists, industry partners, scientists, novel sensor and AI companies, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.
Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in our research, which will be expanded to include analyzing data from wearables and smartphones.
As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.
This is an invite only event.
Agenda
December 09, 2022 - 12PM ET I 9AM PT
1 pm - 1:30 pm ET is a Closed session for Consortia Members only
10 minutes
10 minutes
10 minutes
15 minutes
15 minutes
Welcome/Consortia Updates/Partnerships
Indu Navar - CEO and Founder, EverythingALS
James Berry, MD - Neurologist at MGH
Keynote: Living with ALS perspective
John Driskell Hopkins - GRAMMY Award winner, Zac Brown Band
Speech Study Updates
Ernest Frankel, PhD - MIT
Accelerating pre-competitive Partnerships, ALS Therapies & Digital Biomarkers
Walter Koroshetz, MD - NIH, Deputy Director National Institute of Neurological Disorders and Stroke (NINDS)
Role of Digital Biomarkers & Clinical Endpoints
Brendan O'Leary - FDA, Acting Director, Digital Health Center of Excellence
5 minutes
25 minutes
Open dialogue with NIH & FDA
Moderated by Wendy Ehler
Closing remarks and next steps
Indu Navar